Advertisement
HYFT vs RXRX
Which Stock Would AI Choose? MindWalk Holdings (HYFT) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- Both companies operate at the intersection of artificial intelligence and drug discovery, but they target different points in the value chain: HYFT builds "bio-native" AI data infrastructure and biologics discovery tools, while RXRX is a clinical-stage biotech industrializing its own drug pipeline.
- HYFT reported fiscal 2026 revenue up 46% year-over-year to roughly $15.6 million, with a sharply narrowed net loss and its first recurring platform contracts.
- RXRX has a substantially larger market capitalization and a deep roster of big-pharma partnerships, including a recent Sanofi option exercise that triggered a $10 million milestone payment.
- The two names differ sharply in scale, liquidity, and maturity: RXRX trades with a multi-billion-dollar valuation, while HYFT is a microcap with a materially thinner trading profile.
- Relative performance and market positioning favor RXRX on established institutional sponsorship, while HYFT presents a higher-risk, earlier-stage turnaround narrative.
- You can find more detail on each name's key developments and daily price action by visiting HYFT Major News and HYFT Today's Price Move, as well as RXRX Major News and RXRX Today's Price Move.
- For a data-driven view of how automated strategies are positioning across the market, explore the Trending AI Robots page.
Introduction
Artificial intelligence has become one of the most closely watched themes across the biopharmaceutical sector, but not all "AI biotech" companies are alike. This stock comparison examines HYFT (MindWalk Holdings Corp.) and RXRX (Recursion Pharmaceuticals, Inc.), two publicly traded businesses applying AI to life sciences in fundamentally different ways. MindWalk positions itself as a "bio-native" AI infrastructure and discovery platform, while Recursion operates a clinical-stage, AI-driven drug pipeline backed by major pharmaceutical partners. Growth-oriented investors, sector specialists, and traders evaluating risk-versus-reward in speculative biotech names may find the contrast between these two companies instructive when assessing relative performance and market positioning.
HYFT Overview and Recent Performance
HYFT, formerly known as ImmunoPrecise Antibodies Ltd. and rebranded as MindWalk Holdings Corp. in September 2025, is an Austin, Texas-based "bio-native" AI company. The firm builds what it describes as BioIntelligence infrastructure for life sciences, anchored by its proprietary HYFT technology—a function-aware representation of biological data—and layered applications including its ReefIQ data substrate and LensAI reasoning platform. The company also operates a biologics discovery business with a record of molecules advanced by partners into clinical trials.
Recent market activity has reflected a deliberate strategic pivot. In recent quarters, MindWalk reported three consecutive periods of year-over-year revenue growth, culminating in fiscal 2026 revenue up 46% to approximately $15.6 million, with gross margin expanding to 59%. The company also narrowed its net loss to roughly $14 million from about $30.2 million the prior year and secured its first two contracted recurring platform agreements. Additional developments—including divesting its European operations for non-dilutive proceeds, regaining Nasdaq compliance, and inclusion in Russell microcap indexes—have supported a more constructive sentiment shift. However, the stock remains a microcap with modest cash reserves and unproven scale in its newer software model.
RXRX Overview and Recent Performance
RXRX is Recursion Pharmaceuticals, a clinical-stage biotechnology company that applies machine learning, automation, and large biological datasets to industrialize drug discovery. Recursion operates its own therapeutic pipeline while also monetizing its platform through partnerships with major pharmaceutical companies, including Sanofi, Roche, and Genentech.
Recent weeks have brought a series of notable catalysts. Sanofi exercised an option on a potential first-in-class oral small molecule targeting inflammatory disease, triggering a $10 million milestone payment to Recursion, with additional milestones and royalties possible. The company also announced positive Phase 1b/2 data from its TUPELO trial of REC-4881 in familial adenomatous polyposis (FAP), showing reductions in polyp burden, and priced a roughly $200 million equity offering that management indicated could extend its cash runway into 2029. These developments have coincided with volatile but generally firmer trading, supported by a consensus analyst view that skews toward Buy. Even so, the company continues to report substantial operating losses and remains dependent on milestone revenue and capital raises.
Trending AI Robots
Tickeron maintains a large library of AI trading bots spanning thousands of tickers, each configured with distinct trading styles, strategies, timeframes, performance statistics, and watchlists. Rather than surfacing the entire catalog, Tickeron curates a focused Trending AI Robots section that highlights the strategies best suited to current market conditions. The bots available cover a broad range of approaches—from short-term momentum systems to longer-horizon trend models—giving traders a way to observe how automated, rules-based logic evaluates names like those in this comparison. Browsing the curated selection can offer a useful, data-driven complement to fundamental research, whether you are monitoring a single ticker or scanning the broader market.
Head-to-Head Comparison
The most important distinction between these two stocks is where they sit in the drug-discovery value chain. HYFT is an infrastructure and tools provider: it generates recurring-style revenue from data and discovery services, but its scale remains small and its software model is only beginning to mature. RXRX, by contrast, is an asset-heavy, clinical-stage biotech pursuing its own pipeline while validating its platform through partnerships with global pharma leaders.
Growth drivers also differ. MindWalk's near-term catalysts center on commercial adoption of ReefIQ and LensAI, pipeline progress across its GLP-1, dengue, and influenza programs, and disciplined expense management. Recursion's momentum hinges on clinical readouts, partner milestone payments, and its ability to fund operations without excessive dilution. On risk factors, HYFT carries execution and liquidity risk typical of microcaps, while RXRX carries clinical, regulatory, and ongoing cash-burn risk despite a larger capital base. Sector exposure is broadly similar—both are AI-and-biotech hybrids—but their market sentiment profiles diverge: Recursion enjoys wider institutional coverage and analyst sponsorship, whereas MindWalk is earlier in rebuilding analyst attention.
Tickeron AI Verdict
Based on observable factors such as trend consistency, institutional sponsorship, catalyst density, and relative market positioning, Tickeron's AI would likely favor RXRX at present. Recursion demonstrates a steadier combination of validated partnerships, a more established trading and analytical footprint, and a pipeline of near-term catalysts. HYFT shows improving fundamentals and a credible turnaround narrative, but its thinner liquidity and earlier-stage business model introduce greater uncertainty. As a result, the AI would probably assign a higher probability of more consistent relative performance to RXRX in the current environment, while continuing to monitor HYFT for confirmation that its revenue and platform momentum translate into durable scale.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HYFT is a Hold and RXRX is a Hold.
Momentum Indicator for HYFT turns negative, indicating new downward trend
HYFT saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 83 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HYFT turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 42 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
HYFT moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HYFT crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYFT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for HYFT entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HYFT's RSI Indicator exited the oversold zone, 32 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where HYFT advanced for three days, in 176 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. HYFT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.937) is normal, around the industry mean (3.498). P/E Ratio (0.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.464) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYFT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RXRX in +8.71% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RXRX advanced for three days, in 208 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In 79 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
RXRX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RXRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for RXRX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.063) is normal, around the industry mean (3.498). P/E Ratio (-3.520) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HYFT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 80 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| HYFT | RXRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 80% | N/A |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Advances ODDS (%) | 4 days ago 82% | 4 days ago 84% |
| Declines ODDS (%) | 8 days ago 89% | 10 days ago 85% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HYFT’s FA Score shows that 0 FA rating(s) are green while RXRX’s FA Score has 0 green FA rating(s).
- HYFT’s FA Score: 0 green, 5 red.
- RXRX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HYFT’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).
- HYFT’s TA Score: 3 bullish, 6 bearish.
- RXRX’s TA Score: 3 bullish, 6 bearish.
Price Growth
HYFT (@Biotechnology) experienced а -0.96% price change this week, while RXRX (@Biotechnology) price change was -7.47% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
HYFT is expected to report earnings on Dec 21, 2026.
RXRX is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
HYFT and
Correlation & Price change
A.I.dvisor indicates that over the last year, HYFT has been loosely correlated with RXRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HYFT jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To HYFT | 1D Price Change % | ||
|---|---|---|---|---|
| HYFT | 100% | N/A | ||
| RXRX - HYFT | 49% Loosely correlated | +1.13% | ||
| LPCN - HYFT | 43% Loosely correlated | N/A | ||
| PRME - HYFT | 38% Loosely correlated | +10.26% | ||
| MGX - HYFT | 37% Loosely correlated | +8.04% | ||
| ABCL - HYFT | 37% Loosely correlated | -4.09% | ||
More | ||||
RXRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To RXRX | 1D Price Change % | ||
|---|---|---|---|---|
| RXRX | 100% | +1.13% | ||
| CRSP - RXRX | 66% Loosely correlated | +1.33% | ||
| PRME - RXRX | 62% Loosely correlated | +10.26% | ||
| BEAM - RXRX | 60% Loosely correlated | +2.62% | ||
| ABSI - RXRX | 60% Loosely correlated | +1.50% | ||
| DNA - RXRX | 57% Loosely correlated | -14.65% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ONX | 6.13 | 0.60 | +10.85% |
| Tradr 2X Long ON Daily ETF (ONX) | |||
| NCA | 8.50 | 0.06 | +0.71% |
| Nuveen California Municipal Value Fund | |||
| EWA | 29.40 | -0.01 | -0.03% |
| iShares MSCI Australia ETF (EWA) | |||
| GDXW | 34.63 | -0.57 | -1.62% |
| Roundhill Gold Miners WeeklyPay ETF (GDXW) | |||
| PLTD | 5.07 | -0.10 | -1.93% |
| Direxion Dailly PLTR Bear 1X ETF (PLTD) | |||